ISRCTN10751858已完成不适用
Employing combined neuroimaging techniques and CSF biomarkers to characterise spatiotemporal dynamics in Dementia and Mild Cognitive Impairment
Cognetivity Limited0 个研究点目标入组 90 人开始时间: 2018年2月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Control group:
- •1. Addenbrooke’s Cognitive Examination (Revised/III) score of above 84
- •2. Bristol Activities of Daily Living Scale score of unimpaired” or mildly impaired”
- •3. Capacity to understand the information about the study and to give consent to participate
- •4. Males and females aged between 65-80 years
- •5. Not currently on medication that may interfere with the study results
- •6. In good general health
- •7. Matched for age and education
- •1. A clinical diagnosis of MCI according to ICD-10 criteria, diagnosed by an Old Age Psychiatrist
- •2. Mini Mental State Examination (MMSE) <28 and > 24
- •3. Males and Females aged 65-80 years
- •4. Capable of indicating informed consent for participation
- •Mild-AD group
- •1. A clinical diagnosis of Mild-AD according to ICD-10 criteria, diagnosed by an Old Age Psychiatrist
- •2. Mini Mental State Examination (MMSE) <24 and > 19
- •3. Males and Females aged 65-80 years
- •4. Capable of indicating informed consent for participation
排除标准
- •Control group
- •1. Presence of significant cerebrovascular disease ie. History of CVA
- •2. Major medical co-morbidities e.g. Congestive Cardiac Failure, Diabetes Mellitus with renal impairment
- •3. Major psychiatric disorder eg. Chronic psychosis, recurrent depressive disorder, generalized anxiety disorder
- •4. The use of cognitive enhancing drugs e.g. cholinesterase inhibitors
- •5. A concurrent diagnosis of epilepsy
- •6. A history of alcohol misuse
- •7. A history of illicit drug use
- •8. A history of severe visual impairment, e.g. macular degeneration, diabetic retinopathy, as determined by the clinical team
- •9. A history of repeated head trauma
- •1. Patients who fulfill criteria for a diagnosis of Mild AD
- •2. Major medical co-morbidities e.g. Congestive Cardiac Failure, Diabetes Mellitus with renal impairment
- •3. Major psychiatric disorder eg. Chronic psychosis, recurrent depressive disorder, generalized anxiety disorder
- •4. The use of cognitive enhancing drugs e.g. cholinesterase inhibitors
- •5. A concurrent diagnosis of epilepsy
- •6. A history of alcohol misuse
- •7. A history of illicit drug use
- •Mild-AD group
- •1. Patients who fulfill criteria for a diagnosis of Moderate AD or Other Mild Dementias
- •2. Major medical comorbidities e.g. Congestive Cardiac Failure, Diabetes Mellitus with renal impairment
- •3. Major psychiatric disorder eg. Chronic psychosis, recurrent depressive disorder, generalized anxiety disorder
- •4. A concurrent diagnosis of epilepsy
- •5. A history of alcohol misuse
- •6. A history of illicit drug use
- •7. A history of severe visual impairment, e.g. macular degeneration, diabetic retinopathy, as determined by the clinical team
- •8. A history of repeated head trauma
- •9. MMSE scores less than 19
- •10. Presence of Sleep Apnoea
研究者
相似试验
已完成
不适用
Functional neuroimaging and neurophysiological patterns during Zolpidem-induced behavioral improvement in akinetic mutism: a pilot studyNL-OMON47472Academisch Medisch Centrum2
招募中
不适用
An observational neuroimaging and neurophysiological study investigating the visual pathway in Huntington*s disease.hereditary neurodegenerative movement disorderHuntington's disease1002929910028037NL-OMON45518eids Universitair Medisch Centrum60
招募中
不适用
To explore the neuroimaging mechanism and clinical effect of acupuncture and LF-rTMS on patients after strokestrokeITMCTR2100004773Shenzhen Nanshan People's Hospital
尚未招募
Unknown
Research on neurological disease using neuroimaging database and movement analysisJPRN-UMIN000053240Tokyo Medical and Dental University800
进行中（未招募）
4 期
Can extended treatment with N-pep-12 improve recovery after acute ischemic stroke?ISRCTN15764675The Foundation for the Study of Neuroscience and Neuroregeneration (Fundatia pentru Studiul Nanoneurostiintelor si Neuroregenerarii)107